Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.25 2.04% 62.50 54,242 16:35:18
Bid Price Offer Price High Price Low Price Open Price
61.00 64.00 63.50 63.00 63.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 105.57 -22.57 -5.26 419
Last Trade Time Trade Type Trade Size Trade Price Currency
16:07:19 O 472 63.50 GBX

Benchmark (BMK) Latest News

More Benchmark News
Benchmark Investors    Benchmark Takeover Rumours

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
10/9/202109:53Benchmark Holdings Plc419
19/5/202108:35SALMON prices 30 year high and CAT VACCINES are Go-Go566

Add a New Thread

Benchmark (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-17 15:07:1963.50472299.72O
2021-09-17 15:07:1963.507,5004,762.50AT
2021-09-17 15:07:1963.00715450.45AT
2021-09-17 14:59:2863.00753474.39AT
2021-09-17 14:59:2863.00403253.89O
View all Benchmark trades in real-time

Benchmark (BMK) Top Chat Posts

Benchmark Daily Update: Benchmark Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 61.25p.
Benchmark Holdings Plc has a 4 week average price of 58p and a 12 week average price of 55.50p.
The 1 year high share price is 67p while the 1 year low share price is currently 43p.
There are currently 670,368,484 shares in issue and the average daily traded volume is 31,926 shares. The market capitalisation of Benchmark Holdings Plc is £418,980,302.50.
murdo mcsponge: That's been my belief. If they have come up with either disease resistant shrimp, or a way of stimulating something akin to an immune response, I believe that would be a serious winner with a very big market. I thought that Shrimp didn't have an immune response, and I did ask Malcolm Pye about it at an AGM about 3 or 4 years ago, and he indicated that while they don't have the sort of immune system that we recognize, they do have some sort of system for fighting off infections. If BMK have something, the market should be enormous, and it's one of the main reasons BMK is the biggest holding in my Portfolio.
edmonda: Our fair value per share of 88p represents a near 50% premium to the current price https://www.equitydevelopment.co.uk/research/growth-drivers-aligned-with-aquaculture-sustainability-goals
tomps2: Benchmark Holdings (LON:BMK) interim results presentation to analysts, 18.5.21 by Trond Willliksen, CEO, and Septima Maguire, CFO. Good H1 performance with revenue growth +11% and Adjusted EBITDA +13% reflecting a strong performance in Advanced Nutrition and solid trading in Genetics and Health. Significant progress towards commercialisation of BMK08 and Clean Treat. Positive outlook and trading in line with market expectations, with good revenue visibility for the second half. Https://www.piworld.co.uk/2021/05/19/benchmark-holdings-bmk-interim-results-presentation-to-analysts/
edwardt: yes but it does show that we need firms like bmk trying to improve the welfare of the fish and the health of the oceans.
hedgehog 100: 25/02/2021 07:00 UK Regulatory (RNS & others) OTAQ PLC Non-Executive Director Appointment OTAQ, the marine technology products and solutions group for the global aquaculture and offshore oil and gas industries, is pleased to announce that Malcolm Pye will join the Board of OTAQ as a Non-Executive Director with immediate effect. Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement. Prior to his founding role at Benchmark, Malcolm gained wide experience in the food sector from his various senior management positions within Hillsdown Holdings, operating in animal breeding, poultry production, feed milling and veterinary services. During this time, he developed extensive experience in breeding and genetics, food production/technology, sales (including account lead responsibilities within the UK / international retail sector with a range of bluechip companies including M&S, Tesco and McDonalds) and strategic M&A as well as holding a main board position within the Group. Malcolm's work with Hillsdown Holdings in the early to mid-1990's influenced a career-long focus on sustainable food production which formed the basis and inspiration for the creation of Benchmark Holdings. Alex Hambro, Non-Executive Chairman, commented: "We are really delighted to welcome Malcolm to the Board of OTAQ. Malcolm's experience in, and knowledge of, the global aquaculture industry is unparalleled, and will be of huge benefit to OTAQ as it develops and commercialises additional sustainable technologies and services for the aquaculture farming and producing communities. Our core SealFence acoustic deterrence system has significant opportunities for growth in geographies where Malcolm has built strong long-term relationships. Furthermore, his knowledge of additional farmed species other than salmon will be extremely helpful as we expand our range of products ." Aside from the information set out in the announcement above, no further information is required to be disclosed pursuant to Listing Rule 9.6.13R. https://uk.advfn.com/stock-market/london/otaq-OTAQ/share-news/OTAQ-PLC-Non-Executive-Director-Appointment/84427020
tomps2: Benchmark (BMK) FY20 analyst presentation Trond Williksen, CEO & Spetima Maguire, CFO present FY20 results to analysts. Video: Https://www.piworld.co.uk/2020/12/14/benchmark-bmk-fy20-results-analyst-presentation/ Podcast: Https://www.piworld.co.uk/podcasts/
edmonda: Benchmark Holdings plc transformed operations during FY20 against the challenging macro conditions brought about by Covid-19, completing a fundamental restructuring via nine disposals in a 12-month period. The latter raising up to £44m, with the closure of non-core or loss-making activities allowing a refocus of the business on aquaculture and a rebasing of the cost structure. Consequently, BMK has reinforced its financial position, boosted liquidity by £50m, and appears very well positioned to execute its growth strategy to achieve commercial returns. This leads us to upgrade our FY 21/22 AEBITDA forecasts and to expect a net profit in FY23. The Group is uniquely positioned to build selectively on its leading market positions in aquaculture, notably in developing innovative and sustainable products, diversifying its product range, coupled with a strong focus on profitability and from a position of improved balance sheet strength. We also raise our retained value per share from 63p to 72p on our updated forecasts. While the shares have performed well on the back of successful disposals, those gains look fully justified. https://www.equitydevelopment.co.uk/research/progress-on-the-road-to-profitability
edmonda: Management at Benchmark Holdings are doing as they promised: the disposals program is nearly complete, raising £44m which boosts financial strength. The launch of CleanTreat® + BMK08 to combat sea lice is on track. Equity Development keeps its fair value at 63p/share, read new research note here: https://tinyurl.com/y54mhj3a
36jay: Massive update.Fire work soon.https://www.investegate.co.uk/benchmark-hlgs-plc--bmk-/rns/sale-of-vaccine-manufacturing-assets/202007231105018934T/
edmonda: #BMK Genetics division was resilient, ongoing restructuring and cost containment a priority, DCF valuation of BMK is £421m or 63 pence per share https://research.equitydevelopment.co.uk/research/streamlined-for-growth-and-efficiency
Benchmark share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 06:58:50